Cardiac cachexia

References

• McMurray JJ, Stewart J. Epidemiology, aetiology, and prog-nosis of heart failure. Heart 2000;833:596–602.
   Google Scholar
• Doehner W, Anker SD. Cardiac cachexia in early literature: a review of research prior to Medline. Int J Cardiol 2002;85:7–14.
   PubMedGoogle Scholar
• Anker SD, Coats A JS. Cardiac cachexia: a syndrome with impaired survival and immune and neuroendocrine activa-tion. Chest 1999;115:836–47.
   PubMed Web of Science ®Google Scholar
• Davos CH, Doehner W, Rauchhaus M, Cicoira M, Francis DP, Coats AJ, et al. Body mass and survival in patients with chronic heart failure without cachexia: the importance of obesity. J Card Fail 2003;9:29–35.
   PubMedGoogle Scholar
• Carr JG, Stevenson LW, Walden JA, Heber D. Prevalence and haemodynamic correlates of malnutrition in severe congestive heart failure secondary to ischaemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1989;63:709–13.
   PubMed Web of Science ®Google Scholar
• McMurray J, Abdullah I, Dargie HJ, Shapiro D. Increased concentrations of tumor necrosis factor in `cachectic' patients with severe chronic heart failure. Br Heart J 1991; 66:356–8.
   PubMedGoogle Scholar
• Levine B, Kalman J, Mayer L, Fillit H, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990;323:236–41.
   Google Scholar
• Otaki M. Surgical treatment of patients with cardiac cachexia. An analysis of factors affecting operative mortal-ity. Chest 1994;105:1347–51.
   Google Scholar
• Freeman LM, Roubenoff R. The nutrition implications of cardiac cachexia. Nutr Rev 1994;52:340–7.
   PubMedGoogle Scholar
• Cowie MR, Mosterd A, Wood DA, Deckers JW, Poole-Wilson PA, Sutton GC, et al. The epidemiology of heart failure. Eur Heart J 1997;18:208–25.
   PubMed Web of Science ®Google Scholar
• Kannel WB, Ho K, Thom T. Changing epidemiological features of cardiac failure. Br Heart J 1994;72 (Suppl):53–9.
   Google Scholar
• McGovern PG, Pankow JS, Shahar E, Doliszny KM, Folsom AR, Blackburn H, et al. Recent trends in acute coronary heart disease: mortality, morbidity, medical care, and risk factors. N Engl J Med 1996;334:884–90.
   PubMed Web of Science ®Google Scholar
• Abel RM, Fischer J, Buckley MJ, Barnett GO, Austen WG. Malnutrition in cardiac surgical patients. Arch Surg 1976; 111:45–50.
   Google Scholar
• Blackburn GL, Gibbons GW, Bothe A, Benotti PN, Harken DE, McEnany TM. Nutritional support in cardiac cachexia. J Thorac Cardiovasc Surg 1977;73:489–96.
   PubMedGoogle Scholar
• Anker SD, Ponikowski P, Varney S, Chua TP, Clark AL, Webb-Peploe KM, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet 1997; 349: 1050–3.
   Google Scholar
• Anker SD, Negassa A, Coats AJ, Afzal R, Poole-Wilson PA, Cohn JN, et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet 2003;361:1077–83.
   Google Scholar
• Anker SD, Sharma R. The syndrome of cardiac cachexia. Int J Cardiol 2002;85:51–66.
   PubMed Web of Science ®Google Scholar
• Pittman JG, Cohen P. The pathogenesis of cardiac cachexia. N Engl J Med 1964;271:403–9.
   PubMed Web of Science ®Google Scholar
• Buchanan N, Keen RD, Kinsley R, Eyberg CD. Gastro-intestinal absorption studies in cardiac cachexia. Intensive Care Med 1977;3:89–91.
   PubMedGoogle Scholar
• King D, Smith ML, Chapman TJ, Stockdale HR, Lye M. Fat malabsoprtion in elderly patients with cardiac cachexia. Age Ageing 1996;25:144–9.
   Google Scholar
• Poehlman ET, Scheffers J, Gottlieb S, Fisher ML, Vaiteke-vicus P. Increased resting metabolic rate in patients with congestive heart failure. Ann Intern Med 1994;121:860–2.
   Google Scholar
• Riley M, Elborn JS, McKane WR, Bell N, Stanford CF, Nicholls DP. Resting energy expenditure in chronic heart failure. Clin Sci (Lond) 1991;80:633–9.
   PubMedGoogle Scholar
• Obisesan TO, Toth MJ, Kendall D. Energy expenditure and symptom severity in men with heart failure. Am J Cardiol 1996;77:1250–2.
   Google Scholar
• Poehlman ET, Danfort E. Endurance training increaes metabolic rate and norepinephrine appearance rate in older individuals. Am J Physiol 1991;261:E233–9.
   PubMed Web of Science ®Google Scholar
• Lipkin DP, Jones DA, Round JM, Poole-Wilson PA. Abnormalities of skeletal muscle in patients with chronic heart failure. Int J Cardiol 1988;18:187–95.
   Google Scholar
• Mancini DM, Walter G, Reichek N, Lenkinski R, McCully KK, Mullen JL, et al. Contribution of skeletal muscle atrophy to exercise intolerance and altered muscle metab-olism in heart failure. Circulation 1992;85:1364–73.
   PubMed Web of Science ®Google Scholar
• Harrington D, Anker SD, Chua TP, Webb-Peploe KM, Ponikowski PP, Poole-Wilson PA, et al. Skeletal muscle function and its relation to exercise tolerance in chronic heart failure. J Am Coll Cardiol 1997;30:1758–64.
   Google Scholar
• Anker SD, Swan JW, Volterrani M, Chua TP, Clark AL, Poole-Wilson et al.. The influence of muscle mass, strength, fatigability and blood flow on exercise capacity in cachectic and non-cachectic patients with chronic heart failure. Eur Heart J 1997;18:259–69.
   PubMedGoogle Scholar
• Kotler DP, Tierney AR, Wang J, Pierson RN. Magnitude of body-cell-mass depletion and the timing of death from wasting in AIDS. Am J Clin Nutr 1989;50:i1117.
   Google Scholar
• Anker SD, Clark AL, Teixeira MM, Hellewell PG, Coats AJ. Loss of bone mineral in patients with cachexia due to chronic heart failure. Am J Cardiol 1998;83:612–5.
   Google Scholar
• Anker SD, Ponikowski PP, Clark Al, Leyva F, Rauchhaus M, Kemp M, et al. Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. Eur Heart J 1999;20:683–93.
   PubMed Web of Science ®Google Scholar
• Toth MJ, Gottlieb SS, Goran MI, Fisher ML, Poehlman ET. Daily energy expenditure in free-living heart failure patients. Am J Physiol 1997;272:E469–75.
   Google Scholar
• Doehner W, Rauchhaus M, Florea VG, Sharma R, Bolger AP, Davos CH, et al. Uric acid in cachectic and noncachectic patients with chronic heart failure: relationship to leg vascular resistance. Am Heart J 2001;141:792–9.
   PubMed Web of Science ®Google Scholar
• Volterrani M, Clark AL, Ludman PF, Swan JW, Adamo-poulus S, Piepoli M, et al. Predictors of exercise capacity in chronic heart failure. Eur Heart J 1994;15:801–9.
   Google Scholar
• Ponikowski P, Piepoli M, Chua TP, Banasiak W, Francis D, Anker SD, et al. The impact of cachexia on cardiorespiratory reflex control in chronic heart failure. Eur Heart J 1999;20: 1667–75.
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Anker SD, Chua TP, Francis D, Banasiak W, Poole-Wilson PA, et al. Oscillatory breathing patterns during wakefulness in patients with chronic heart failure: clinical implications and role of augmented peripheral chemosensi-tivity. Circulation 1999;100:2418–24.
   Google Scholar
• Ponikowski P, Francis DP, Piepoli MF, Davies LC, Chua TP, Davos CH, et al. Enhanced ventilatory response to exercise in patients with chronic heart failure and preserved exercise tolerance: marker of abnormal cardiorespiratory reflex control and predictor of poor prognosis. Circulation 2001; 103:967–72.
   PubMed Web of Science ®Google Scholar
• Florea VG, Henein MY, Rauchhaus M, Koloczek V, Sharma R, Doehner W, et al. The cardiac component of cardiac cachexia. Am Heart J 2002;144:45–50.
   PubMed Web of Science ®Google Scholar
• Niebauer J, Pflaum CD, Clark AL, Strasburger CJ, Hooper J, Poole-Wilson PA, et al. Deficient insulin-like growth factor I in chronic heart failure predicts altered body composition, anabolic deficiency, cytokine and neurohormonal activation. J Am Coll Cardiol 1998;32:393–7.
   Google Scholar
• Anker SD, Volterrani M, Pflaum CD, Strasburger CJ, Osterziel KJ, Doehner W, et al. Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone. J Am Coll Cardiol 2001; 38:443–52.
   PubMed Web of Science ®Google Scholar
• Anker SD, Chua TP, Ponikowski P, Harrington D, Swan JW, Kox WJ, et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 1997;96:526–34.
   PubMed Web of Science ®Google Scholar
• Goldstein DS. Plasma norepinephrine as an indicator of sympathetic neural activity in clinical cardiology. Am J Cardiol 1981;48:1147–54.
   PubMed Web of Science ®Google Scholar
• Lommi J, Kupari M, Yki- Jarvinen H. Free fatty acid kinetics and oxidation in congestive heartfailure. Am J Cardiol 1998; 81:45–50.
   Google Scholar
• Obisesan TO, Toth MJ, Donaldson K, Gottlieb SS, Fisher ML, Vaitekevicius P, et al. Energy expenditure and symptom severity in men with heart failure. Am J Cardiol 1996;77: 1250–2.
   PubMedGoogle Scholar
• Staroukine M, Devriendt J, Decoodt P, Verniory A. Relationships between plasma epinephrine, norepinephrine, dopamine and angiotensin II concentrations, renin activity, hemodynamic state and prognosis in acute heart failure. Acta Cardiol 1984;39:131–8.
   PubMedGoogle Scholar
• Brink M, Wellen J, Delafontaine P. Angiotensin II causes weight loss and decreases circulating insulin-like growth factor Tin rats through a pressor-independent mechanism. J Clin Invest 1996;97:2509–16.
   Google Scholar
• Bolger AP, Sharma R, Li W, Leenarts M, Kalra PR, Kemp M, et al. Neurohormonal activation and the chronic heart failure syndrome in adults with congenital heart disease. Circulation 2002;106:92–9.
   PubMed Web of Science ®Google Scholar
• Anand IS, Ferrari R, Kalra GS, Wahi PL, Poole-Wilson PA, Harris PC. Edema of cardiac origin. Studies of body water and sodium renal function, hemodynamic indexes, and plasma hormones in untreated congestive cardiac failure. Circulation 1989;80:299–305.
   Google Scholar
• Nicholls MG, Espiner EA, Donald RA, Hughes H. Aldos-terone and its regulation during diuresis in patients with gross congestive heart failure. Clin Sci Mol Med 1974;47: 301–15.
   PubMedGoogle Scholar
• Anker SD, Clark AL, Kemp M, Salsbury C, Teixeira MM, Hellewell PG, et al. Tumor necrosis factor and steroid metabolism in chronic heart failure: possible relation to muscle wasting. J Am Coll Cardiol 1997;30:997–1001.
   PubMed Web of Science ®Google Scholar
• Dutka DP, Elborn JS, Delamere F, Shale DJ, Morris GK. Tumor necrosis factor alpha in severe congestive heart failure. Br Heart J 1993;70:141–3.
   Google Scholar
• Hasper D, Hummel M, Kleber FX, Reindl I, Volk HD. Systemic inflammation in patients with heart failure. Eur Heart J 1998;19:761–5.
   Google Scholar
• Seta Y, Shan K, Bozkurt B, Oral H, Mann DL. Basic mechanisms in heart failure: the cytokine hypothesis. J Card Fail 1996;3:243–9.
   Google Scholar
• Torre-Amione G, Kapadia S, Lee J, Durand JB, Bies RD, Young JB, et al. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation 1996;93:704–11.
   Google Scholar
• Clark AL, Loebe M, Potapov EV, Egerer K, Knosalla C, Hetzer R, et al. Ventricular assist device in severe heart failure: effects on cytokines, complement and body weight. Eur Heart J 2001;22:2275–83.
   PubMedGoogle Scholar
• Anker SD, Egerer KR, Volk HD, Kox WJ, Poole-Wilson PA, Coats AJ. Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. Am J Cardiol 1997;79: 1426–30.
   Google Scholar
• Niebauer J, Volk HD, Kemp M, Dominguez M, Schumann RR, Rauchhaus M, et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 1999;353:1838–42.
   PubMed Web of Science ®Google Scholar
• Von Haehling S, Genth-Zotz S, Anker SD, Volk HD. Cachexia: a therapeutic approach beyond cytokine antagon-ism. Int J Cardiol 2002;85:173–83.
   PubMed Web of Science ®Google Scholar
• Vonhof S, Brost B, Stille-Siegener M, Grumbach I, Kreuzer H, Figulla H. Monocyte activation in congestive heart failure due to coronary artery disease and idiopathic dilated cardio-myopathy. Int J Cardiol 1998;63:237–44.
   Google Scholar
• Genth-Zotz S, von Haehling S, Bolger AP, Kalra PR, Coats A JS, Anker SD. Pathophysiological quantities of endotoxin induce tumor necrosis factor release in whole blood from patients with chronic heart failure. Am J Cardiol 2002;90: 1226–30.
   Google Scholar
• Bolger AP, Sharma R, von Haehling S, Doehner W, Oliver B, Rauchhaus M, et al. Effect of interleukin-10 on the produc-tion of tumor necrosis factor-alpha by peripheral blood mononuclear cells from patients with chronic heart failure. Am J Cardiol 2002;90:348–9.
   Google Scholar
• Brunkhorst FM, Clark AL, Forycki ZF, Anker SD. Pyrexia, procalcitonin, immune activation and survival in cardiogenic shock: the potential importance of bacterial translocation. Int J Cardiol 1999;72:3–10.
   PubMed Web of Science ®Google Scholar
• Rauchhaus M, Coats A J, Anker SD. The endotoxin-lipoprotein hypothesis. Lancet 2000;356:930–3.
   PubMed Web of Science ®Google Scholar
• Rauchhaus M, Koloczek V, Volk H, Kemp M, Niebauer J, Francis DP, et al. Inflammatory cytokines and the possible immunological role for lipoproteins in chronic heart failure. Int J Cardiol 2000;76:125–33.
   PubMed Web of Science ®Google Scholar
• Horwich TB, Hamilton MA, Maclellan WR, Fonarow GC. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail 2002;8:216–24.
   PubMed Web of Science ®Google Scholar
• Rauchhaus M, Clark AL, Doehner W, Davos C, Bolger A, Sharma R, et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol 2003;42:1933–40.
   PubMed Web of Science ®Google Scholar
• Tsujinaka T, Fujita J, Ebisui C, Yano M, Kominami E, Suzuki K, et al. Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice. J Clin Invest 1996;97:244–9.
   PubMed Web of Science ®Google Scholar
• Barton BE. IL-6: insights into novel biological activities. Clin Immunol Immunopathol 1997;85:16–20.
   PubMedGoogle Scholar
• Cicoira M, Bolger AP, Doehner W, Rauchhaus M, Davos C, Sharma R, et al. High tumor necrosis factor-alpha levels are associated with exercise intolerance and neurohormonal activation in chronic heart failure patients. Cytokine 2001; 15:80–6.
   PubMedGoogle Scholar
• Tracey KJ, Morgello S, Koplin B, Fahey TJ, Fox K, Aledo A. Metabolic effects of cachectin/tumor necrosis factor are modified by site of production: Cachectin/tumor necrosis factor-secreting tumor in skeletal muscle induces chronic cachexia, while implantation in brain induces predominantly acute cachexia. J Clin Invest 1990;86:2014–24.
   PubMed Web of Science ®Google Scholar
• Bolger AP, Anker SD. Tumor necrosis factor in chronic heart failure: a peripheral view on pathogenesis, clinical manifes-tations and therapeutic implications. Drugs 2000;60:1245–57.
   PubMedGoogle Scholar
• Yoshizumi M, Perrella MA, Burnett JC, Lee ME. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res 1993;73: 205–9.
   PubMed Web of Science ®Google Scholar
• Anker SD, Volterrani M, Egerer KR, Felton CV, Kox WJ, Poole-Wilson PA, et al. Tumor necrosis factor alpha as a predictor of impaired peak leg blood flow in patients with chronic heart failure. Q J Med 1998;91:199–203.
   Google Scholar
• Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedmann JM. Positional cloning of the mouse ob gene and its human homologue. Nature 1994;372:425–32.
   PubMed Web of Science ®Google Scholar
• Leyva F, Anker SD, Egerer K, Stevenson JC, Kox WJ, Coats AJ. Hyperleptinaemia in chronic heart failure. Relationships with insulin. Eur Heart J 1998;19:1547–51.
   PubMed Web of Science ®Google Scholar
• Murdoch DR, Rooney E, Dargie HJ, Shapiro D, Morton JJ, McMurray JJ. Inappropriately low plasma leptin concentra-tion in the cachexia associated with chronic heart failure. Heart 1999;82:352–6.
   PubMed Web of Science ®Google Scholar
• Filippatos GS, Tsilias K, Venetsanou K, Karambinos E, Manolatos D, Kranidis A, et al. Leptin serum levels in cachectic heart failure patients. Relationship with tumor necrosis factor-alpha system. Int J Cardiol 2000;76:117–22.
   Google Scholar
• Doehner W, Pflaum CD, Rauchhaus M, Godsland IF, Egerer K, Cicoira M, et al. Leptin, insulin sensitivity and growth hormone binding protein in chronic heart failure with and without cardiac cachexia. Eur J Endocrinol 2001;145:727–35.
   PubMedGoogle Scholar
• Ferrari R, Bachetti T, Confortini R, Opasich C, Febo 0, Corti A, et al. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation 1995;92:1479–86.
   Google Scholar
• Rauchhaus M, Doehner W, Francis DP, Davos C, Kemp M, Liebenthal C, et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 2000;102:3060–7.
   PubMed Web of Science ®Google Scholar
• Sharma R, Rauchhaus M, Ponikowski PP, Varney S, Poole-Wilson PA, Mann DL, et al. The relationship of erythrocyte sedimentation rate to inflammatory cytokines and survival in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 2000;36: 523–8.
   Google Scholar
• Leyva F, Anker SD, Godsland IF, Teixeira M, Hellewell PG, Kox WJ, et al. Uric acid in chronic heart failure: a marker of chronic inflammation. Eur Heart J 1998;19:1814–22.
   PubMed Web of Science ®Google Scholar
• Anker SD, Doehner W, Rauchhaus M, Sharma R, Francis D, Knosalla C, et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 2003;107:1991–7.
   PubMed Web of Science ®Google Scholar
• Doehner W, Schoene N, Rauchhaus M, Leyva-Leon F, Pavitt DV, Reaveley DA, et al. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation 2002;105: 2619–24.
   Google Scholar
• Farquharson CA, Butler R, Hill A, Belch JJ, Struthers AD. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 2002;106:221–6.
   Google Scholar
• Cappola TP, Kass DA, Nelson GS, Berger RD, Rosas GO, Kobeissi ZA, et al. Allopurinol improves myocardial effi-ciency in patients with idiopathic dilated cardiomyopathy. Circulation 2001;104:2407–11.
   PubMed Web of Science ®Google Scholar
• Broquist M, Arnquist H, Dahlström U, Larsson J, Nylander E, Permert J. Nutritional assessment and muscle energy metabolism in severe chronic congestive heart failure-effects of long-term dietary supplementation. Eur Heart J 1994;15: 1641–50.
   Google Scholar
• McGandy RB, Russel RM, Hartz SC, Jacob RA, Tannen-baum S, Peters H, et al. Nutritional status survey of healthy non-institutionalized elderly: energy and nutrient intake from three-day diet records and nutrient supplements. Nutr Res 1986;6:785–98.
   Google Scholar
• Moriwaki H, Tajika M, Miwa Y, Kato M, Yasuda I, Shiratori Y, et al. Nutritional pharmacotherapy of chronic liver disease: from support of liver failure to prevention of liver cancer. J Gastroenterol 2000;35(Suppl 12):13–7.
   PubMedGoogle Scholar
• Heymsfield SB, Casper K. Congestive heart failure: clinical management by use of continuous nasoenteric feeding. Am J Clin Nutr 1989;50:539–44.
   PubMedGoogle Scholar
• Witte KKA, Clark AL, Cleland JGF. Chronic heart failure and micronutrients. J Am Coll Cardiol 2001;37:1765–74.
   PubMed Web of Science ®Google Scholar
• Belch JJF, Bridges AB, Scott N, Chopra M. Oxygen free radicals and congestive heart failure. Br Heart J 1991; 65: 245–8.
   PubMedGoogle Scholar
• Nishiyama Y, Ikeda H, Haramaki N, Yoshida N, Imaizumi T. Oxidative stress is related to exercise intolerance in patients with heart failure. Am Heart J 1998;135:115–20.
   Google Scholar
• Herbaczynska-Cedro K, Kosiewicz-Wasek B, Cedro K. Supplementation with vitamins C and E suppresses leukocyte oxygen free radical production in patients with myocardial infarction. Eur Heart J 1995;16:1044–9.
   PubMedGoogle Scholar
• Coats AJ, Adamopoulos S, Meyer TE, Conway J, Sleight P. Effects of physical training in chronic heart failure. Lancet 1990;335:63–6.
   Google Scholar
• Coats AJ, Adamopoulos S, Radaelli A, McCance A, Meyer TE, Bernardi L, et al. Controlled trial of physical training in chronic heart failure. Exercise performance, hemodynamics, ventilation, and autonomic function. Circulation 1992; 85: 2119–31.
   Google Scholar
• Anker SD, Negassa A, Coats AJ, Afzal R, Poole-Wilson PA, Cohn JN, et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet 2003;361:1077–83.
   Google Scholar
• Endres S, Ghorbani R, Kelly VE, Georgilis K, Lonnemann G, van der Meer JW, et al. The effect of dietary supplementa-tion with n-3 polyunsaturated fatty acids on the synthesis of IL-1 and tumor necrosis factor by mononuclear cells. N Engl J Med 1989;320: 265–71.
   Google Scholar
• Kremer JM, Jubiz W, Michalek A, Rynes RI, Bartholomew LE, Bigaoutte J, et al. Fish-oil fatty acid supplementation in active rheumatoid arthritis: a double-blinded, controlled, crossover study. Ann Intern Med 1987;106:497–503.
   PubMed Web of Science ®Google Scholar
• Freeman LM, Rush JE, Kehayias JJ, Ross JN Jr, Meydani SN, Brown DJ, et al. Nutritional alterations and the effect of fish oil supplementation in dogs with heart failure. J Vet Intern Med 1998;12: i10 8.
   Google Scholar
• Goldenburg MM. Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis. Clin Ther 1999;21:75–87.
   PubMedGoogle Scholar
• Moreland LW. Inhibitors of tumor necrosis factor for rheumatoid arthritis. J Rheumatol 1999;26:7–15.
   PubMed Web of Science ®Google Scholar
• Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340:1398–405.
   Google Scholar
• Sharma R, Anker SD. Cytokines, apoptosis and cachexia: the potential for TNF antagonism. Int J Cardiol 2002;85:161–71.
   PubMed Web of Science ®Google Scholar
• Anker SD. Has the time arrived to use anticytokine therapy in chronic heart failure? Dial Cardiovasc Med 2000;5:162–70.
   Google Scholar
• Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004;109:1594–602.
   PubMed Web of Science ®Google Scholar
• Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Anti-TNF Therapy Against Congestive Heart Failure In-vestigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003; 107:3133–40.
   Google Scholar
• Anker SD, Coats AJS. How to RECOVER from RENAIS-SANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol 2002;86:123–30.
   PubMed Web of Science ®Google Scholar
• Sliwa K, Skudicky D, Candy G, Wisenbaugh T, Sareli P. Randomised investigation of effects of pentoxiphylline on left-ventricular performance in idiopathic dilated cardiomyo-pathy. Lancet 1998;351:1091–3.
   Google Scholar
• Skudicky D, Bergmann A, Sliwa K, Candy G, Sareli P. Beneficial effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitors and carvedilol: results of a randomized study. Circulation 2001;103:1083–8.
   Google Scholar
• Matsumori A, Shioi T, Yamada T, Matsui S, Sasayama S. Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure. Circulation 1994;89:955–8.
   Google Scholar
• Sharma R, Anker SD. Immune and neurohormonal pathways in chronic heart failure. Congest Heart Fail 2002;8:23–8.
   PubMedGoogle Scholar
• Osterziel KJ, Strohm 0, Schuler J, Friedrich M, Hanlein D, Willenbrock R, et al. Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyo-pathy. Lancet 1998;351:1233–7.
   Google Scholar
• Cuneo RC, Wilmshurst P, Lowy C, McGauley G, Sonksen PH. Cardiac failure responding to growth hormone. Lancet 1989;1:838–9.
   Google Scholar
• O'Driscoll JG, Green DJ, Ireland M, Kerr D, Larbalestier RI. Treatment of end-stage cardiac failure with growth hor-mone. Lancet 1997;349:1068.
   PubMed Web of Science ®Google Scholar
• Nagaya N, Kangawa K. Ghrelin improves left ventricular dysfunction and cardiac cachexia in heart failure. Curr Opin Pharmacol 2003;3:146–51.
   PubMed Web of Science ®Google Scholar
• Cicoira M, Kalra PR, Anker SD. Growth hormone resistance in chronic heart failure and its therapeutic implications. J Card Fail 2003;9:219–26.
   Google Scholar
• Sigurdsson A, Swedberg K, Ullmann B. Effects of ramipril on the neurohormonal response to exercise in patients with mild or moderate congestive heart failure. Eur Heart J 1994;15: 247–54.
   Google Scholar
• Van Veldhuisen DJ, Genth-Zotz S, Brouwer J, Boomsma F, Netzer T, Man In T Veld A J, et al. High- versus low-dose ACE, inhibition in chronic heart failure: a double-blind, placebo-controlled study of imidapril. J Am Coll Cardiol 1998;32:1811–8.
   Google Scholar
• Liu L, Zhao SP. The changes in circulating tumor necrosis factor levels in patients with congestive heart failure influenced by therapy. Int J Cardiol 1999;69:77–82.
   PubMedGoogle Scholar
• Gullestad L, Aukrust P, Ueland T, Espevik T, Yee G, Vagelos R, et al. Effect of high- versus low-dose angiotensin con-verting enzyme inhibition on cytokine levels in chronic heart failure. J Am Coll Cardiol 1999;34:2061–7.
   PubMed Web of Science ®Google Scholar
• Corbalan R, Acevedo M, Godoy I, Jalil J, Campusano C, Klassen J. Enalapril restores depressed circulating insulin-like growth factor 1 in patients with chronic heart failure. J Card Fail 1998;4:115–9.
   PubMedGoogle Scholar
• Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Hisanaga T, et al. Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure. J Am Coll Cardiol 2000;35:714–21.
   PubMed Web of Science ®Google Scholar
• Coats A JS, Anker SD, Roecker EB, Schultz MK, Staiger C, Shusterman N, et al. Prevention and reversal of cardiac cachexia in patients with severe heart failure by carvedilol: results of the COPERNICUS study. Circulation 2001;104:II-437 (abstract).
   Google Scholar
• Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 1993;22:6A–13A.
   Google Scholar